Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications.


Journal

Vascular medicine (London, England)
ISSN: 1477-0377
Titre abrégé: Vasc Med
Pays: England
ID NLM: 9610930

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 23 6 2020
medline: 23 9 2020
entrez: 23 6 2020
Statut: ppublish

Résumé

Vascular malformations occur during early vascular development resulting in abnormally formed vessels that can manifest as arterial, venous, capillary or lymphatic lesions, or in combination, and include local tissue overdevelopment. Vascular malformations are largely caused by sporadic somatic gene mutations. This article aims to review and discuss current molecular signaling pathways and therapeutic targets for vascular malformations and to classify vascular malformations according to the molecular pathways involved. A literature review was performed using Embase and Medline. Different MeSH terms were combined for the search strategy, with the aim of encompassing all studies describing the classification, pathogenesis, and treatment of vascular malformations. Major pathways involved in the pathogenesis of vascular malformations are vascular endothelial growth factor (VEGF), Ras/Raf/MEK/ERK, angiopoietin-TIE2, transforming growth factor beta (TGF-β), and PI3K/AKT/mTOR. These pathways are involved in controlling cellular growth, apoptosis, differentiation, and proliferation, and play a central role in endothelial cell signaling and angiogenesis. Many vascular malformations share similar aberrant molecular signaling pathways with cancers and inflammatory disorders. Therefore, selective anticancer agents and immunosuppressants may be beneficial in treating vascular malformations of specific mutations. The current classification systems of vascular malformations, including the International Society of the Study of Vascular Anomalies (ISSVA) classification, are primarily observational and clinical, and are not based on the molecular pathways involved in the pathogenesis of the condition. Several molecular pathways with potential therapeutic targets have been demonstrated to contribute to the development of various vascular anomalies. Classifying vascular malformations based on their molecular pathogenesis may improve treatment by determining the underlying nature of the condition and their potential therapeutic target.

Identifiants

pubmed: 32568624
doi: 10.1177/1358863X20918941
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

364-377

Auteurs

Calver Pang (C)

Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department of Surgical Biotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, United Kingdom.

Chung Sim Lim (CS)

Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department of Surgical Biotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, United Kingdom.
NIHR, University College London Hospitals Biomedical Research Centre, London, United Kingdom.

Jocelyn Brookes (J)

Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department of Interventional Radiology, Royal Free London NHS Foundation Trust, London, United Kingdom.

Janice Tsui (J)

Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department of Surgical Biotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, United Kingdom.
NIHR, University College London Hospitals Biomedical Research Centre, London, United Kingdom.

George Hamilton (G)

Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department of Surgical Biotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH